Target intelligence / Profile preview

Immunological synapse

Molecular classification
Other (specialized multicellular interface composed of receptors, adhesion molecules, and cytoskeletal components)
01

Overview

The immunological synapse is a highly organized and dynamic interface formed at the point of contact between a cytotoxic immune cell (such as a cytotoxic T lymphocyte or natural killer cell) and a target cell, such as a tumor cell. It is not a single molecule but a multiprotein structure composed of antigen receptors (e.g., T cell receptor), adhesion molecules, co-stimulatory/checkpoint receptors, and cytoskeletal elements from both the immune and tumor cell sides. The synapse mediates recognition, signaling, and targeted cytotoxicity. Recent research shows tumor cells can remodel their actin cytoskeleton and secrete vesicles at the synapse, potentially contributing to immune evasion. The structure and function of the immunological synapse are central to the effectiveness of many immunotherapies, including checkpoint inhibitors and CAR-T cells. This entry should be flagged as not being a specific molecular target, but rather an important conceptual and structural entity in tumor immunology.

Other names
Immune synapseImmunologic synapseISLytic synapse
02

Mechanism of action

Modulation of immune synapse formation (checkpoint blockade enhances T cell effector functions at the synapse); Enhancing immune cell activation or cytotoxicity through engagement or stabilization of the immunological synapse (e.g., BiTEs crosslink T cells and tumor antigens to promote synapse structure)

03

Biological functions

Immune responseSignal transductionCytotoxicity (via T cell or NK cell attack)Cell-cell communication
04

Disease associations

Cancer (tumor-immune interactions)Infection (pathogen targeting)Autoimmunity (mistargeted responses)
05

Safety considerations

Possibility of off-target or excessive immune activation causing autoimmunity or cytokine release syndromeTumor evasion through synaptic remodeling or secretion of immunosuppressive vesicles
06

Interacting drugs

Immune checkpoint inhibitors (such as anti-PD-1, anti-CTLA-4)

2 more in the full profile.

07

Biomarkers

Expression of antigen-presenting molecules (e.g., MHC, tumor antigen)Engagement of adhesion molecules (e.g., CD2-CD58, integrins)Presence of immune activation markers at the synapse (e.g., CD63 on tumor side indicating vesicle secretion)

Beyond the preview

Go deeper on Immunological synapse.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunological synapse.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call